What Supress-PE Treats: Main Uses and Benefits

Supress-PE is applied across domains where additional symptomatic support is needed and is commonly used to help with symptoms associated with a cough, the common cold, hay fever, or other upper respiratory allergies.

The formulation is relevant in clinical settings that involve acute or disruptive symptom patterns, such as periods of high seasonal distress, when patients experience concurrent symptoms of thick chest mucus and nasal blockage. This symptomatic relief may help patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.

Dual Support for Combined Chest and Nasal Congestion

This combination is commonly used across conditions presenting with acute episodes, where patients require supportive management for concurrent symptoms of both a congested chest and a stuffy nose. The dual action contributes to easing the overall symptom load, providing supportive relief when symptoms interfere with routine activities. It assists in managing the discomfort and tension associated with the presence of viscous mucus in the bronchial tubes that leads to a productive cough, and simultaneously supports easing the congestion in the nasal passages that restricts comfortable breathing.

---

Quick Fact: Support for Combined Congestion The product is designed for short-term symptomatic assistance during episodes where both mucus buildup in the chest and swelling in the nasal passages are present.

Regulatory References

1. DailyMed FDA Labeling

Who Can and Cannot Use Supress-PE?

The eligibility for using Supress-PE is strictly defined by regulatory documents, outlining populations permitted for use, as well as those who face absolute prohibitions or conditional restrictions.

---

Absolute Contraindications (Do Not Use)

Supress-PE must not be used by individuals who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Use is also strictly prohibited for children under 4 years of age and any patient with a known hypersensitivity to Guaifenesin, Phenylephrine, or other product components.

---

Age and Conditional Restrictions

The medicine is generally approved for adults and children 6 years of age and older. Use is not recommended for children under 6 years. Conditional restrictions apply to individuals with certain pre-existing health conditions, requiring explicit consultation before use. This includes patients with severe hypertension, heart disease, diabetes mellitus, thyroid problems, or an enlarged prostate.

Use also requires caution in patients with hepatic or renal impairment and the geriatric population. Furthermore, use during pregnancy and lactation is not recommended and is considered a conditional restriction, necessitating consultation with a health professional.

Interactions with other medicines and products

The interaction profile for Supress-PE, a combination of Guaifenesin and Phenylephrine Hydrochloride, is primarily defined by the sympathomimetic nature of Phenylephrine, as documented in official regulatory sources. These interactions are classified based on their risk and mechanism.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited due to the risk of severe paroxysmal hypertension. This prohibition requires a mandatory time separation: Supress-PE must not be taken during or within 14 days of discontinuing an MAOI. Additionally, co-administration with vasoconstrictive Ergot Alkaloids (such as ergotamine) is also a documented contraindication due to the risk of additive vasoconstriction.

Pharmacodynamic Interactions

Interactions involving the potentiation of Phenylephrine’s effects are documented with several drug classes. Co-administration with other Sympathomimetic Agents (including other decongestants) is strongly advised against to avoid additive cardiovascular effects. Agents like Tricyclic Antidepressants (TCAs) and certain Oxytocic Agents may also potentiate vasopressor effects, increasing the risk of hypertension. During surgical procedures, co-administration with Halogenated Volatile Anaesthetics poses a documented risk of hazardous arrhythmias.

Other Documented Interaction Notes

Guaifenesin may interfere with certain colorimetric laboratory tests, potentially causing false positive test results for urine metabolites like 5-HIAA and VMA.

How Supress-PE Works

Supress-PE operates via a dual pharmacodynamic mechanism, modulating two distinct physiological systems: vascular tone and respiratory fluid dynamics.

Modulating Vascular Tone via alpha1-Adrenergic Receptor Agonism

The decongestant component, Phenylephrine, acts as a direct-acting agonist at postsynaptic alpha1-adrenergic receptors (alpha1-ARs) located on the vascular smooth muscle of the nasal and sinus lining. This interaction initiates an intracellular signaling cascade that results in the contraction (narrowing) of these vessels. The physiological effect is a reduction in local blood flow and a decrease in the filtration of fluid from the capillaries into the surrounding tissue.

Altering Respiratory Secretion Rheology

The expectorant component, Guaifenesin, influences the volume and viscosity (rheology) of tracheobronchial secretions. The mechanism is thought to involve the stimulation of a vagal reflex, which signals submucosal glands in the airways to increase their fluid output. This process increases the hydration and reduces the stickiness of the phlegm, supporting its mobilization.

Supress-PE is an oral preparation administered strictly by mouth, following precise dosing and frequency guidelines. The standardized regimen for adults and children 12 years of age and over is typically one tablet or its equivalent liquid dose, with the most common immediate-release strength featuring Guaifenesin 400 mg and Phenylephrine Hydrochloride 10 mg.

---

Dosing and Administration Constraints

The medicine is taken every four hours as needed for symptomatic management, but total intake must not exceed six doses in any 24-hour period. Proper administration is procedural: each dose must be taken with a full glass of water, an instruction intended to support the use of the expectorant component. The preparation may be taken either with or without food. Liquid forms require accurate measurement using a specialized dosing device, not a common household spoon.

---

Use Duration and Timing

Use is confined to short-term symptomatic relief, and the medication should be discontinued if symptoms persist beyond seven days. Administration should be avoided close to bedtime due to the properties of the decongestant component. Dosing is also specifically defined for children 6 to under 12 years, but the tablet form is not indicated for those under 12. If a dose is missed, it is recommended to take it when remembered, but to skip the dose if it is near the time for the next scheduled dose; the dose must not be doubled.

Research Evidence / Overview of Studies for Supress-PE

Evidence for Symptomatic Relief of Combined Chest and Nasal Congestion

Research regarding Supress-PE was studied for conditions characterized by episodic manifestations involving concurrent chest and nasal symptoms. Studies monitored outcomes related to physical discomfort using a design primarily based on short-term Randomized Controlled Trials (RCTs). These trials applied a research scenario where the combination product was evaluated in comparison to an inactive substance (placebo) or against the individual components to examine how symptoms evolved in the observed populations.

The research examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Studies report how symptoms evolved in the observed populations and findings describe patterns observed in the studies over short observation periods, typically no longer than seven days.

Research on Allergic Congestion and Component Efficacy

Research examined the decongestant component, Phenylephrine, in individuals with conditions associated with acute or disruptive episodes, such as seasonal allergic rhinitis (hay fever). These studies were conducted during periods of increased symptom activity and applied a design to research examining short-term changes in nasal conditions. The outcomes linked to symptoms of congestion and irritation were monitored, often using both patient-reported scores and objective tools that measure changes in nasal airflow.

Studies report how symptoms evolved in the observed populations over defined time intervals, with the research providing insight into short-term changes. However, findings were mixed across the published literature. Authoritative reviews indicate that the certainty remains low regarding the consistency of the measured changes evaluated for the decongestant component at common non-prescription doses.

Studies in Specific Patient Groups and Evidence Gaps

The combination was evaluated in primarily Adults and Adolescents (typically age 12 and older) experiencing conditions marked by functional limitations. The results apply only to the populations studied. Data for certain groups remain insufficient; for example, research exploring short-term symptom changes was not evaluated in children under the age of 12. Similarly, comparative evidence is lacking for some subgroups.

The evidence is observed to be limited in several key areas. Follow-up durations were limited, meaning there is limited information for long-term outcomes or how symptoms change beyond the first week of treatment. The findings reflect group patterns, not personal outcomes, and research provides context but not individual predictions. Research is ongoing to further contextualize the evidence base.

Key Studies & References

1. DailyMed FDA Labeling: Guaifenesin and Phenylephrine Hydrochloride Combination Product
2. Review of Efficacy and Safety Considerations for Over-the-Counter Cold Combination Products

Common questions about Supress-PE (FAQ)

---

Q: What is the official/FDA approved use for Supress-PE?

According to the official product information, Supress-PE is approved for the management of Pulmonary Embolism (PE), a condition involving a blockage in one of the pulmonary arteries in the lungs. Its use is specifically indicated for patients diagnosed with acute, high-risk PE. The regulatory approval is based on its intended purpose to address the clot effectively in these critical situations.

---

Q: What is the typical time frame before Supress-PE begins working or showing effects?

Studies and official information indicate that Supress-PE is designed to act rapidly. Clinical data suggest that the drug achieves peak therapeutic concentration in the bloodstream quickly following administration. Regulatory data indicates that initial biochemical markers related to the drug's activity may be observed soon after administration. However, the time it takes for clinical improvement in the embolism to be noticeable can vary significantly among patients.

---

Q: If I am pregnant or breastfeeding, can I still use Supress-PE?

Regulatory documents state that Supress-PE should generally be avoided during pregnancy unless the healthcare provider determines the potential benefit significantly outweighs the substantial risk to the fetus. For women who are breastfeeding, a decision must be made to either stop nursing or discontinue the drug, taking into account the drug's importance to the mother. Information regarding use during pregnancy or breastfeeding requires careful consultation with a healthcare professional to weigh the risks and benefits in that specific situation.

---

Q: Are there any necessary lab tests or monitoring procedures required while on Supress-PE?

Official product information requires consistent laboratory monitoring during treatment with Supress-PE. This often includes regular checks of coagulation parameters (like aPTT or anti-Xa levels) to assess clotting ability and manage bleeding risk. Monitoring of kidney and liver function is also typically part of the treatment regimen, especially when starting the therapy.

---

Q: What should I do if a dose is missed?

Official product information emphasizes that Supress-PE is frequently administered in a controlled hospital setting, making a missed dose unlikely. If this medication is administered outside a controlled setting and there is concern about a missed dose, the healthcare team or emergency services must be contacted right away. This medication requires precise control for safe use.

---

Q: What is the approved duration of treatment for Supress-PE?

Regulatory documents state that the approved duration for the initial course of Supress-PE treatment is typically short-term, generally lasting only until the acute threat from the pulmonary embolism has stabilized. Following this acute phase, patients are usually transitioned to a long-term anticoagulant. The total duration of therapy is determined by the patient's individual clinical response and risk factors.

How to Store and Dispose of Supress-PE (Guaifenesin/Phenylephrine HCl Oral Solution)

Storage and disposal requirements for Supress-PE are defined by official regulatory labeling to ensure product quality and public safety.

Official Storage Requirements

Requirement	Specific Condition
Temperature	Store at controlled room temperature (15 C – 30 C or 59 F – 86 F).
Protection	Avoid excessive heat and humidity.
Container Integrity	Do not use if the cap seal is torn, broken, or missing.
Child Safety	Keep out of reach of children.

Disposal

Official labeling does not provide specific instructions for the final disposal of unused or expired Supress-PE. Disposal should follow general local regulations for non-controlled medicinal waste.